Policy / Pricing FDA accelerated approval path needs improvement, says ICER PharmaphorumThe FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.Policy / PricingRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER. Policy / PricingRead full story Post navigation Previous: Lilly says Foundayo safety confirmed in ACHIEVE-4 trialNext: Obesity’s explosive growth continues as Q1 deals exceed total 2025 value Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
